MXPA05011343A - Materiales particulados. - Google Patents

Materiales particulados.

Info

Publication number
MXPA05011343A
MXPA05011343A MXPA05011343A MXPA05011343A MXPA05011343A MX PA05011343 A MXPA05011343 A MX PA05011343A MX PA05011343 A MXPA05011343 A MX PA05011343A MX PA05011343 A MXPA05011343 A MX PA05011343A MX PA05011343 A MXPA05011343 A MX PA05011343A
Authority
MX
Mexico
Prior art keywords
less
coformulation
active substance
particulate materials
particle
Prior art date
Application number
MXPA05011343A
Other languages
English (en)
Inventor
Sharon Daintree Linda
Original Assignee
Nektar Therapeutics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0310636A external-priority patent/GB0310636D0/en
Application filed by Nektar Therapeutics Uk Ltd filed Critical Nektar Therapeutics Uk Ltd
Publication of MXPA05011343A publication Critical patent/MXPA05011343A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe una coformulacion de particulas, cada particula comprende un nucleo de una sustancia activa rodeada por un recubrimiento de excipiente, las particulas tienen un diametro medio en volumen de 10 (m o menor, las cuales despues de la administracion oral liberan la sustancia activa a una velocidad tal que el tiempo (Tmax) tomado para alcanzar la concentracion activa maxima en la corriente sanguinea, es de una hora o menos. La coformulacion puede ser elaborada utilizando un proceso de formacion de particulas SCF NektarMR.
MXPA05011343A 2003-05-08 2004-05-05 Materiales particulados. MXPA05011343A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0310636A GB0310636D0 (en) 2003-05-08 2003-05-08 Particulate materials
GB0329964A GB0329964D0 (en) 2003-05-08 2003-12-24 Particulate materials
PCT/GB2004/001935 WO2004098561A2 (en) 2003-05-08 2004-05-05 Particulate materials

Publications (1)

Publication Number Publication Date
MXPA05011343A true MXPA05011343A (es) 2005-12-12

Family

ID=32510407

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011343A MXPA05011343A (es) 2003-05-08 2004-05-05 Materiales particulados.

Country Status (10)

Country Link
US (1) US7354601B2 (es)
EP (1) EP1624862B1 (es)
JP (1) JP2006525303A (es)
KR (1) KR20060015587A (es)
AU (1) AU2004237131B2 (es)
BR (1) BRPI0409962A (es)
CA (1) CA2524773C (es)
GB (1) GB2401547B (es)
MX (1) MXPA05011343A (es)
WO (1) WO2004098561A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687542B2 (en) 1996-05-17 2010-03-30 Kowa Pharmaeuticals America, Inc. Rapidly bioavailable tablet and capsule formulations of diclofenac
US6974595B1 (en) 1996-05-17 2005-12-13 Proethic Pharmaceuticals, Inc. Pharmaceutical compositions based on Diclofenae
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB9810559D0 (en) * 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
US20040251192A1 (en) * 2003-05-02 2004-12-16 Karl Fritze Crossflow filtration system with quick dry change elements
EP1624862B1 (en) 2003-05-08 2014-12-31 Nektar Therapeutics Particulate materials
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
US20070026073A1 (en) * 2005-07-28 2007-02-01 Doney John A Amorphous efavirenz and the production thereof
JP2007176869A (ja) * 2005-12-28 2007-07-12 Univ Meijo 難溶性薬物含有微細粒子
US7700125B2 (en) 2006-02-07 2010-04-20 Kowa Pharmaceuticals America, Inc. Moisture resistant container systems for rapidly bioavailable dosage forms
US7939561B2 (en) 2006-02-07 2011-05-10 Apr Applied Pharma Research S.A. Blister packaging for acute pain regimens
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
EP2077823B1 (en) 2006-10-11 2012-06-27 Crititech, Inc. Method for precipitation of small medicament particles into use containers
US20080131504A1 (en) * 2006-12-01 2008-06-05 Mission Pharmacal Co. Short Term Slow Release Drug Delivery System
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
WO2008092046A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Amorphous oxcarbazepine and the production thereof
EP2125938A2 (en) * 2007-01-26 2009-12-02 Isp Investments Inc. Formulation process method to produce spray dried products
EP2120875B1 (en) 2007-02-11 2018-07-11 Map Pharmaceuticals Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
TW201008569A (en) * 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
WO2012159960A1 (en) * 2011-05-20 2012-11-29 Aventis Pharmaceuticals Inc. Pharmaceutical composition comprising fexofenadine
CN115321908B (zh) * 2022-08-10 2023-05-16 河南金诺混凝土有限公司 基于高品质机制砂的高性能混凝土及其制备方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE418247B (sv) 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
US4582731A (en) 1983-09-01 1986-04-15 Battelle Memorial Institute Supercritical fluid molecular spray film deposition and powder formation
US4514574A (en) 1984-01-09 1985-04-30 The Dow Chemical Company Process for separating isomeric mixtures
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4737384A (en) 1985-11-01 1988-04-12 Allied Corporation Deposition of thin films using supercritical fluids
US5219575A (en) 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
DE3787533T2 (de) 1987-12-21 1994-01-20 Union Carbide Corp Verwendung von superkritischen Flüssigkeiten als Verdünner beim Aufsprühen von Überzügen.
DE3744329A1 (de) 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
JPH01176437A (ja) 1987-12-29 1989-07-12 Ono Pharmaceut Co Ltd 有機物質の微粒化方法
US5066522A (en) 1988-07-14 1991-11-19 Union Carbide Chemicals And Plastics Technology Corporation Supercritical fluids as diluents in liquid spray applications of adhesives
DE68907062T2 (de) 1988-10-05 1993-10-07 Upjohn Co Feinverteiltes feste kristalline pulver durch niederschlag in einem anti-lösungsmittel.
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US5232707A (en) 1989-07-10 1993-08-03 Syntex (U.S.A.) Inc. Solvent extraction process
US5219574A (en) 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5106659A (en) 1989-10-04 1992-04-21 Nordson Corporation Method and apparatus for spraying a liquid coating containing supercritical fluid or liquified gas
US4970093A (en) 1990-04-12 1990-11-13 University Of Colorado Foundation Chemical deposition methods using supercritical fluid solutions
US5015481A (en) 1990-05-03 1991-05-14 G. D. Searle & Co. Stabilized pharmaceutical admixture composition
CA2044706C (en) 1990-06-15 2003-02-25 Michael Midler Jr. Crystallization method to improve crystal structure and size
US5037912A (en) 1990-07-26 1991-08-06 The Goodyear Tire & Rubber Company Polymerization of 1,3-butadiene to trans-1,4-polybutadiene with organolithium and alkali metal alkoxide
DE4118230A1 (de) 1990-12-20 1992-06-25 Bayer Ag Verfahren zur isolierung von polymeren aus ihren loesungsmitteln mit kohlendioxid-haltigen fluessigkeiten
DE4041563A1 (de) 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
DE4117751A1 (de) 1991-05-30 1992-12-03 Bayer Ag Verfahren zur isolierung von polycarbonaten
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5196575A (en) 1992-02-19 1993-03-23 Hoechst Celanese Corp. Supercritical separation of isomers of functional organic compounds at moderate conditions
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
JPH08503721A (ja) 1992-11-02 1996-04-23 フェロー コーポレイション 塗装材料の製造方法
DE59308043D1 (de) 1993-02-24 1998-02-26 Sulzer Chemtech Ag Reinigung von salzbeladenem Abwasser durch Nassoxidation bei superkritischen Bedingungen
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US5554382A (en) 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
GB9313650D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
WO1995013132A1 (en) 1993-11-08 1995-05-18 The Gillette Company Method of forming particles using a supercritical fluid, aerogel particles formed thereby, and antiperspirants containing aerogel particles
IT1265473B1 (it) 1993-12-30 1996-11-22 Otefal Srl Procedimento per la produzione di polveri a granulometria controllata e prodotto in polvere cosi' ottenuto
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5635210A (en) 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
SI9400079B (sl) 1994-02-15 2003-02-28 Dr. Weidner Eckhard, Dipl. Ing. Postopek in naprava za pridobivanje in frakcioniranje majhnih delcev iz raztopin nasičenih s plinom
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5560543A (en) 1994-09-19 1996-10-01 Board Of Regents, The University Of Texas System Heat-resistant broad-bandwidth liquid droplet generators
MX9504934A (es) 1994-12-12 1997-01-31 Morton Int Inc Revestimientos en polvo de pelicula delgada lisa.
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US6576264B1 (en) 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
EP0885038B1 (en) 1996-03-01 2011-06-15 The University Of Kansas Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
FR2753639B1 (fr) 1996-09-25 1998-12-11 Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede
IL129242A0 (en) 1996-10-01 2000-02-17 Cima Labs Inc Taste-masked microcapsule compositions and methods of manufacture
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
GB9702799D0 (en) 1997-02-12 1997-04-02 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
GB9800936D0 (en) 1997-05-10 1998-03-11 Univ Nottingham Biofunctional polymers
GB9804379D0 (en) 1998-03-02 1998-04-22 Bradford Particle Design Ltd Method of particle formation
SE9801287D0 (sv) 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
GB9810559D0 (en) 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
US6387410B1 (en) 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
SE9804003D0 (sv) 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
SE9804001D0 (sv) 1998-11-23 1998-11-23 Astra Ab New process
EP2260836B1 (en) 1998-11-25 2016-08-10 Cima Labs Inc. Rapid release tablet with coated drug-containing core and surrounding taste masking layer
SE9901667D0 (sv) 1999-05-07 1999-05-07 Astra Ab Method and device for forming particles
GB9915975D0 (en) 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
FR2795962B1 (fr) 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
GB9920558D0 (en) 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6656492B2 (en) 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
FR2815540B1 (fr) 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0102075D0 (en) 2001-01-26 2001-03-14 Astrazeneca Ab Process
TW586963B (en) 2001-07-20 2004-05-11 Nektar Therapeutics Uk Ltd Method and apparatus for preparing target substance in particulate form and fluid inlet assembly for said apparatus
GB0117696D0 (en) 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
EP1478349A1 (en) * 2002-02-21 2004-11-24 Amarin Development AB A method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
AU2003209673B2 (en) 2002-03-08 2007-10-18 M/S. Ind-Swift Limited Tasteless directly compressible fast-dissolving complexes and pharmaceutical formulations thereof
EP1624862B1 (en) 2003-05-08 2014-12-31 Nektar Therapeutics Particulate materials

Also Published As

Publication number Publication date
BRPI0409962A (pt) 2006-04-25
EP1624862A2 (en) 2006-02-15
GB2401547A (en) 2004-11-17
EP1624862B1 (en) 2014-12-31
CA2524773A1 (en) 2004-11-18
GB2401547B (en) 2005-07-20
US20050170000A1 (en) 2005-08-04
CA2524773C (en) 2014-04-08
WO2004098561A2 (en) 2004-11-18
GB0409973D0 (en) 2004-06-09
AU2004237131A1 (en) 2004-11-18
KR20060015587A (ko) 2006-02-17
US7354601B2 (en) 2008-04-08
JP2006525303A (ja) 2006-11-09
AU2004237131B2 (en) 2009-09-10
WO2004098561A3 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
MXPA05011343A (es) Materiales particulados.
EE200200151A (et) Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend
WO2003024396A3 (en) Dry powder medicament formulations
WO2002043702A3 (en) Pharmaceutical compositions for inhalation
IL169880A0 (en) Compositions formed of coated particles having active ingredients in the particle and in the coating and methods for the preparation thereof
AU5804300A (en) Method for producing morphologically uniform micro and nanoparticles using micromixers
WO2003020241A3 (en) Functional powders for oral delivery
JP2004505761A5 (es)
SI1196146T1 (sl) Praĺ kasti delci z gladko povrĺ ino za uporabo pri inhalacijski terapiji
WO2002013786A3 (en) Method of forming microparticles
WO2006085101A3 (en) Pharmaceutical compositions useful in the transmucosal administration of drugs
WO2004060433A3 (en) Delivery devices
CA2430318A1 (en) Powder formulation and method for producing the same
ES2195408T3 (es) Microparticulas perforadas y procedimientos de uso.
WO2002072033A3 (en) Chronotherapeutic dosage forms containing glucocorticosteroid
CA2258554A1 (en) Method for providing dense particle compositions for use in transdermal particle delivery
WO2007028512A3 (de) Magnetfeld-gesteuerter wirkstofftransfer für die aerosoltherapie
WO2004017918A9 (en) Method of preparing dry powder inhalation compositions
WO2004028504A8 (en) Modified release dosage forms
DE60234945D1 (de) Pulver zur nasalen verabreichung von wirkstoffen
AU2001293900A1 (en) Combination particles for the treatment of asthma
WO2006041843A3 (en) Pharmaceutical dosage form comprising meloxicam
DE602004023478D1 (de) Geschmacksmaskierte beschichtete teilchen, verfahren zur herstellung und in der mundhöhle dispergierbare tabletten enthaltend die beschichteten teilchen
WO2003090715A3 (en) Particulate materials
AU2003268890A1 (en) Cosmetic and dermatological agent containing magnetic particles, production thereof, and use of the same

Legal Events

Date Code Title Description
FG Grant or registration